• Diamond Lake Minerals purchased a 24% stake in Avrio Worldwide PBC in a strategic investment opportunity
• Avrio has partnered with HUMBL Financial to acquire the HUMBL Financial brand, products, and services
• Avrio also announced a 1:10 share exchange agreement, resulting in a bi-directional common stock acquisition between the company and SocialTrader.AI
• SocialTrader will deploy Avrio’s digital financial market infrastructure to access public, private, and digital markets across multiple asset classes

Diamond Lake Minerals (OTC: DLMI), a multi-strategy operating company on a path to emerging as a pioneering force in the development of digital assets and SEC-registered security tokens, recently announced a strategic investment into Avrio Worldwide PBC, purchasing a 24% stake in the company. Avrio is a registered market infrastructure provider with a full technology stack and recently acquired the HUMBL Financial brand, products, and services (https://ibn.fm/xbFRN).

Avrio is the parent company of a portfolio of companies that deliver licensed digital financial market infrastructure and solutions across public, private, and digital markets. Avrio’s partnership with HUMBL Financial provides HUMBL with the global market access needed to efficiently execute its strategies and scale rapidly in a competitive and complex market environment across stocks, options, crypto, commodities, and digital assets – including traditional financial products and services customers would expect inside digital wallets and web platforms.

“HUMBL Financial has developed new and innovative products, such as the BLOCK Indexes and BLOCK ETXs, that give retail investors new ways to access digital assets and also deliver a range of new consumer financial products and services into digital wallets and web3 platforms,” said Lawrence Wintermeyer, CEO of Avrio. “HUMBL becomes a significant stakeholder in Avrio with this agreement, and we look forward to representing the HUMBL Financial brand and shareholders across the Avrio platform and network.”

In addition to the HUMBL Financial acquisition, Avrio also announced a 1:10 share exchange agreement, resulting in a bi-directional common stock acquisition between the company and SocialTrader.AI. SocialTrader will offer AI-driven investment strategies, risk management, and education for the new generation of traders and investors using the company’s global digital financial market infrastructure. This deal marks another milestone for Avrio’s ecosystem of companies that will develop and scale new, innovative digital financial products and services across multiple markets (https://ibn.fm/S71vw).

SocialTrader is an AI-powered, consumer fintech platform providing affordable access to professional investing tools. Its advanced investment platform combines AI, quantitative trading, investment strategies, and risk management with robust security. The company will deploy Avrio’s digital financial market infrastructure to access public, private, and digital markets across multiple asset classes.

Alfonso Arana, Co-founder and CEO of SocialTrader, said Avrio’s state-of-the-art digital financial market infrastructure will power the SocialTrader platform with cost-efficient, secure, and reliable access to global markets. “The experience of its management team of traders, quants, and investment managers will be invaluable in supporting SocialTrader through the development of its next-generation product roadmap, allowing its users to invest in stocks, options, commodities, ETXs, and quantitative investment products that will expand the range and depth of access to assets and markets for global retail investors,” Arana added.

Avrio’s public market technology includes an API farm for exchange management (“EM”), order management (“OM”), portfolio management (“PM”), and client management (“CM”), as well as routes to global public markets. Avrio’s NFT technology provides exchange access and capabilities to trade digital assets and collectibles.

For more information, visit the company’s website at www.DiamondLakeMinerals.com or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

In addition, for information on the company’s security token SEC-regulated exchange partner INX and the development of the INX Way, visit https://www.inx.co/inx-ebook/. This free security token bible, written with the SEC on the rollout of security tokens and the future of digital assets, will greatly deepen your understanding of security tokens.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• Advanced Gold Exploration in January 2024 closed the first tranche of a non-brokered private placement for aggregate gross proceeds of $62,500
• A continuing private placement is in progress and will be closed soon
• In December 2023, the company exercised its option to acquire a 75% interest in certain mineral claims located in Melba Township in the Kirkland Lake Area of Ontario
• In October 2023, Advanced Gold Exploration acquired an option on the Landrum gold property in South Carolina from Carolina Gold Resources
• The company announced in September 2023 it would change its corporate name to Advanced Gold Exploration Inc.

Advanced Gold Exploration (CSE: AUEX) (OTC: AUHIF) (FSE: 4TG), formerly Advance United Holdings Inc., is a junior mining company bringing an entirely different approach to the mining industry. Advanced Gold Exploration doesn’t intend to become a mining company. Rather, it has acquired a portfolio of undervalued gold properties and is increasing their value through the application of modern technology. The object is to eventually monetize the projects to add value for its shareholders.

Advanced Gold Exploration has a growing pipeline of similar properties that it is looking to acquire. The company is involved exclusively in the acquisition and advancement of past gold projects – with no intent to bring them back into production. It leaves the actual gold mining to others who are experts in that area.

Advanced Gold Exploration’s expertise is in identifying and acquiring undervalued properties with significant historical work which were previously not economically viable, but that the company believes have economic value at today’s gold prices. Advanced Gold Exploration funds the reworking of historic data and applying modern technology to underwrite new qualified reports that document quantifiable resources and reserves to current standards, thereby recognizing the current value of the projects.

The company’s purpose is to bring immediate and long-term value to its partners and shareholders while seeking to eliminate exploration risk. Advanced Gold Exploration believes that the future of gold is strong, and it will be part of that future.

The company is headquartered in Toronto.

Projects

The Melba Property is the site of a former producing gold mine located about 15 kilometers north of the gold mining center of Kirkland Lake, Ontario. The project is located in the Abitibi Greenstone Belt, part of the largest gold producing area of Canada. Visible gold can be identified in quartz veins on the surface and high-grade gold intersections have been obtained in drilling by AUEX. No exploration has been carried out on the extensions of the veins to the north or south of the surface exposures in swamp covered areas.

The Doyle Property lies in the Batchawana Greenstone Belt located north of Sault Ste. Marie, Ontario. Past drilling identified high-grade gold deposits in three areas of the property. Follow up studies are needed on all three sites. Exploration has not been carried out to follow-up the high-grade gold intersections. Further work will focus on expanding the areas of known gold mineralization.

The Landrum Property in Edgefield County, South Carolina, is in the Carolina Gold Belt, home of at least five past producing gold mines and one currently producing gold mine. The area was the site of the first gold rush in the U.S. in the early 1800s, predating 1849 California. The area has recently become of interest due to gold bearing intersection on a nearby property where 62.5 meters graded 8.5 G/t gold in a recent drillhole. Gold can still be panned in some streams in the area. Identified veins consist of silicified zones generally made up of 20-50% and vary in thickness from less than a meter to 10 meters.

The Paint Lake Road Property is located in Wawa, Ontario, and is less than five kilometers from Wesdome’s operating Mishi Open Pit gold mine. Gold deposits have been found to the north, east and south of the property. A recent geophysical survey on the neighboring property has pointed to a prospective mineralized horizon which appears to trend onto the property.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

Recently the gold price has reached new highs on multiple days and is tracing a trend upward.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Management Team

James Atkinson, M.Sc., P. Geo., is CEO of Advanced Gold Exploration. An experienced exploration geologist and project manager with over 50 years of experience, he has spent his career in mineral exploration and mining. He has designed and managed multimillion dollar programs searching for and discovering various commodities, including industrial minerals. These projects involved geophysical, geochemical and drilling programs, as well as prospecting and geological mapping. He has also negotiated options and purchase deals for mineral properties and raised financing for exploration. He recently completed a transaction which resulted in cash and shares to the company. The result was a special distribution of publicly trading shares to the existing shareholders.

Andrew Ramcharan, Ph.D., P. Eng., is President of Advanced Gold Exploration. He has 20 years’ unique experience in the mining industry, which includes investor relations, project evaluation, operations, capital markets, consultancy and investment banking. He has a track record of growing companies significantly, with recent success at Roscan Gold with over $100 million of value creation in less than 14 months. He has created and implemented investor relations policies and corporate strategies with significant success. He completed over 300 project evaluations globally on many commodities, proposed over 40 for different investment strategies and completed two majors take over (worth of $800 million and $1.5 billion in capital cost). He directly assisted in putting four mines in production and significant growth of numerous companies, including IAMGOLD. At Sprott, he was conducting project evaluation and successfully deployed over $500 million – the most deals in any year.

Radovan Danilovsky, CIM, is CFO of Advanced Gold Exploration. He is an experienced small-cap executive in the junior mining sector. He is also an experienced investment manager and currently is a registered Portfolio Manager with Wealthera Inc. He has served as a Managing Director, Portfolio Manager and Chief Compliance Officer of Orthogonal Capital Management Corp. Prior to that, he was an investment analyst at Accilent Capital Management Inc. He is a graduate of the University of Toronto and earned master’s degrees from UPMC Sorbonne University and ESSEC Business School in Paris.

For more information, visit the company’s website at www.AdvancedGoldExploration.com.

NOTE TO INVESTORS: The latest news and updates relating to AUHIF are available in the company’s newsroom at https://ibn.fm/AUHIF

• Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases
• PaxMedica is focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms
• The ASD therapeutics market was valued at $2.01 billion in 2023 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9%
• There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the condition’s symptoms rather than targeting the pathophysiology itself

Researchers used to believe that autism spectrum disorder only affected one in 2,500 children – today, that estimation is closer to one in 36 children. Between 1998 and 2018, research has found more than a 780% increase in the number of autism cases in the United Kingdom. This significant increase is partially due to the deeper understanding and awareness of autism and the number of physicians who can diagnose the condition (https://ibn.fm/o5oTZ).

Autism spectrum disorder (“ASD”) is a developmental disorder affecting how individuals interact with other people, behavior, communication, and learning. This disorder can be diagnosed at any age, but symptoms often appear in the first two years of life. There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the condition’s symptoms rather than targeting the pathophysiology itself.

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms, is on a promising path to address the unmet medical needs of ASD, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

PaxMedica is developing a robust lineup of products aimed at addressing ASD and associated neurodevelopmental conditions. Their flagship product under development holds promise in mitigating or even easing some of the most challenging factors of ASD, potentially facilitating smoother integration of autistic individuals into social settings and enhancing their quality of life.

At the forefront of PaxMedica’s initiatives are PAX-101 and PAX-102, leveraging the company’s exclusive source of suramin sodium, a broad-acting anti-purinergic therapy with a century-long history. Their ongoing endeavors encompass:

• PAX-101 (IV Suramin) for ASD – Having concluded a Phase 2B study in 2021 involving 52 subjects across six sites in South Africa, PAX-101 exhibits promising results in ASD management. Suramin’s efficacy, demonstrated in a dose range study, underscores its potential as a therapeutic agent for ASD, with findings presented to AACAP in October 2021.
• PAX-102 (Intranasal Suramin) – PaxMedica’s innovative intranasal suramin formulation is presently undergoing evaluation for its efficacy in ASD and other neurodevelopmental conditions.
• PAX-101 for HAT – Capitalizing on suramin’s historical usage in treating Human African Trypanosomiasis (“HAT”), PaxMedica is advancing PAX-101 as a therapeutic solution for this ailment, particularly focusing on early-stage East African HAT cases.
• Selective Anti-Purinergic Therapies – PaxMedica’s exploration extends to other APTs through preclinical studies targeting specific purinergic receptors. These investigations aim to uncover therapies that offer tailored benefits beyond suramin’s broad spectrum of action.

The ASD therapeutics market was valued at $2.01 billion in 2023 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9% (https://ibn.fm/lvMzA). There are many factors expected to influence this growth, including the growing prevalence of the disease globally, the rising awareness about ASD and the available options for treatment, and growing interest by investors making investments in R&D initiatives for effective drugs to treat ASD.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

• D-Wave’s new go-to-market (“GTM”) growth strategy, initially focused on key verticals, including logistics, manufacturing, and government, is expected to accelerate the adoption and deployment of commercial quantum technologies
• The GTM approach reinforces the value of the company’s unique annealing quantum computing solutions, which help organizations solve highly complex computational problems today
• According to Hyperion Research, over 80% of enterprises are expected to increase their investments in quantum computing over the next two to three years, with logistics and supply chain management identified as top sectors to benefit from quantum computing capabilities

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently launched a new go-to-market (“GTM”) growth strategy to accelerate the adoption and deployment of commercial quantum technologies. The GTM move extends D-Wave’s position in commercial quantum computing and is initially focused on key verticals, including logistics, manufacturing, and government. The strategy reinforces how the company’s unique annealing quantum computing solutions can help organizations solve complex computational problems today (https://ibn.fm/blzr2).

According to a Hyperion Research report, commissioned by D-Wave, (https://ibn.fm/iOLGW), more than 80% of enterprises surveyed expect to increase their investments in quantum computing over the next two to three years, with logistics and supply chain management identified as top sectors to benefit from quantum computing capabilities. The new GTM strategy sharpens the company’s focus to drive revenue and help customers incorporate D-Wave’s technologies more rapidly into their IT infrastructures. It comes at a time when D-Wave is focused on transitioning customers from experimentation to operational use of quantum.

In support of the company’s vertical strategy for the GTM initiative, D-Wave recently launched a logistics-focused campaign, introducing new resources and highlighting subject matter expertise on how annealing quantum computing is uniquely suited to solve critical logistics challenges. Elements of this campaign include:

• A new ebook (https://ibn.fm/rpXRM): “Moving Forward: How Quantum-Powered Logistics Management is Changing the Game”
• A LinkedIn Live session, which took place on March 7, 2024 with Murray Thom, vice president of quantum technology evangelism at D-Wave, focused on optimization solutions for logistics (https://ibn.fm/OHzLh)
• An upcoming logistics-focused webinar on March 26, 2024, featuring Tecnalia, a technological development center, showcasing how they use quantum hybrid technologies to reduce storage costs and improve vehicle space allocation in their truck-loading application (https://ibn.fm/MfGnN)

“Our new GTM strategy positions us to better serve a market that is ready to reap the tangible benefits of today’s quantum computing solutions,” said Irwan Owen, VP of growth at D-Wave. “We expect this strategic focus will expand our reach and deliver greater value for our customers and shareholders as we help businesses solve today’s real-world optimization challenges.”

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 companies use D-Wave technologies. The company boasts an extensive IP portfolio featuring over 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

The company also recently announced its involvement in the upcoming 36th Annual Roth Conference, to be held March 17-19, where CEO Dr. Alan Baratz and CFO John Markovich will participate. The conference will be held at the Ritz Carlton, Laguna Niguel in Dana Point, California. Dr. Baratz will also participate in a fireside chat, which will be webcast live and archived for future viewing.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding expected growth in investment in quantum computing; the potential impact and expected results of D-Wave’s new GTM strategy; D-Wave’s participation in the 36th Annual Roth Conference; and its planned activities at the conference. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including  the risk that the conference is rescheduled or cancelled; unforeseen changes to travel plans or budgets; general economic conditions and other risks; the company’s ability to expand the company’s customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on its business; the risk that the company will need to raise additional capital to execute the company’s business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that its securities will not maintain the listing on the NYSE; the risk that the company’s restatement of certain previously issued audited and unaudited financial statements or material weaknesses in internal controls could negatively affect investor confidence and raise reputational issues; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

• Lexaria, a global innovator in drug delivery platforms, highlighted results from its DIAB-A22-1 animal study, highlighting a 7% reduction in weight and a 19.9% reduction in blood glucose
• With this success, Lexaria looks to kick off its WEIGHT-A24-1 animal study to examine diabetes and weight loss effects of its patented DehydraTECH(TM)-processed GLP-1 drugs and DehydraTECH-processed CBD
• The study will comprise 12 arms and involve 72 animals. It will run for a total of 12 weeks
• This study will build on previous studies that evidenced DehydraTECH’s potential to enable greater penetration of GLP-1 drugs into the brain tissue

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released highlights from its DIAB-A22-1 animal study on rodents. The study sought to explore the overall efficiency of its patented DehydraTECH(TM)-CBD formulation and its impact on conditions associated with diabetes. This 8-week study resulted in a 7% reduction in weight, as well as a 19.9% reduction in blood glucose, aligning with other study works in animals that pointed to the known anti-inflammatory and antioxidant properties of CBD functioning to lessen some of the essential pathophysiological factors associated with diabetes (https://ibn.fm/1XpLx).

With the success of this study, Lexaria looks to kick off its WEIGHT-A24-1 animal study that will seek to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 (“GLP-1”) drugs and DehydraTECH-processed cannabidiol alone and in combination. This study will be executed by a Health Canada-licensed Canadian research laboratory and is set to commence within 45 days (https://ibn.fm/wrpAD).

This study will comprise 12 arms, 8 of which composition manufacturing has already been completed. Each arm is expected to be dosed for twelve weeks following an acclimation period, during which over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for the purposes of detailed pharmacokinetic drug delivery analyses. The remaining study arms, 9 through 12, will kick off later due to some information outputs required from the other study arms.

With WEIGHT-A24-1, Lexaria looks to build on the success of its previous studies, including the goal of evidencing DehydraTECH’s potential to enable greater penetration of GLP-1 drugs into the brain tissue. Industry studies have evidenced that small peptide GLP-1R agonists activate a subset of GLP-1R-expressing neurons in the arcuate nucleus involved in weight loss (https://ibn.fm/h1yrv). Having expressed its resolve to focus on GLP-1 studies for the 2024 calendar year, the WEIGHT-A24-1 study is one of several planned for 2024.

It highlights the company’s commitment to its course and creating shareholder value. It also reflects its commitment to further developing its DehydraTECH technology and opening it up to more areas of application that offer value to individuals and companies alike. As Lexaria looks to embark on three human studies this year, including a 12-week chronic dosing human study as well as long-term stability testing, WEIGHT-A24-1 will play an integral role in shaping their outcome and affirming the overall effectiveness of its DehydraTECH technology.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Life EV Group in December 2023 announced its acquisition of a 40% interest in LEV Manufacturing through a share exchange
• LEV Manufacturing Inc. in July 2023 acquired Serial 1 Cycle Company, an e-bike maker founded by Harley-Davidson
• In February 2022, the company announced a name change to Life Electric Vehicles Holdings Inc.
• In November 2021, Second Street Capital Inc. merged with Life Electric Vehicles Holdings Inc.

Life Electric Vehicles Holdings (OTC: LFEV) (d/b/a Life EV Group), along with its subsidiaries, is a developer, manufacturer and distributor in the light electric vehicle industry. The company’s business model focuses on the launch, acquisition and consolidation of multiple brands of e-bikes, e-trikes, e-scooters and light EVs with the aim of positioning itself as an industry leader for the American micro-mobility market.

The light electric vehicle industry, mainly e-bikes, is fast becoming a leading form of EV sales in the U.S. and Europe. In addition to offering ready-to-ride electric vehicles, Life EV Group intends to distribute individual components, including motors, batteries, chargers, controllers and EV parts, to third party manufacturers in both the U.S. and worldwide.

The company’s first acquisition was completed in 2023 with a 40% equity stake in LEV Manufacturing Inc., a related company and American manufacturer of e-bikes. LEV Manufacturing’s assembly utilizes free-trade zone processes with a U.S. Certificate of Origin, eliminating middle layer costs and resulting in cost-effective production and lower MSRPs.

LEV Manufacturing recently completed the acquisition of Serial 1 Cycle Company LLC. Serial 1 is an e-bike maker founded by U.S. motorcycle manufacturer Harley-Davidson in 2018 and spun off as an independent brand in 2020. The acquisition positions Serial 1 for even greater success and long-term growth.

Life EV Group is headquartered in Deerfield Beach, Florida.

Market Opportunity

An analysis from Mordor Intelligence, a market research and advisory firm, estimates the e-bike market to be worth $34.98 billion in 2024 and projects it will expand to reach a value of $51.78 billion by 2029, representing a CAGR of 8.16% during the forecast period.

Mordor attributes forecast market growth primarily to the increasing adoption of electric bikes as a mode of daily transportation around the world. The market is seeing an upsurge in unit sales based on their attractive consumer characteristics, including health benefits, affordability and convenience.

The North American electric bike market is growing as the preference for low-speed two- and three-wheelers has increased in recent years. Various bike-sharing operators are including electric bikes in their fleets, which is expected to support the sales growth of these bikes in the near future.

Management Team

Robert Provost is the CEO of Life EV Group. He was Founder and CEO of Prodeco Technologies, a maker of e-bikes and e-bike parts and accessories. He also serves as President and CEO of LEV Manufacturing Inc. He is Chairman of the board for Serial 1 Cycle Company.

Daniel Del Aguila is COO at Life EV Group. He co-founded Prodeco Technologies and serves as COO of LEV Manufacturing Inc.

Ivan Drusc is CFO at Life EV Group. He is a seasoned accounting and finance professional with a proven track record in industries from insurance to IT and property management. He has served as a key player in businesses ranging in size from startups to publicly traded global companies. He has experience in cost reduction, risk mitigation, IT and ERP systems, outsourcing and restructuring. He is a graduate of the University of Akron with a bachelor’s degree in accounting.

For more information, visit the company’s website at www.LifeElectricVehicles.com.

NOTE TO INVESTORS: The latest news and updates relating to LFEV are available in the company’s newsroom at https://ibn.fm/LFEV

• The global electric boats market is forecast to more than double in size, increasing from $3.3 billion in 2023 to $7.7 billion by 2030
• Vision Marine’s unveiling of its newest e-boat offering, the Phantom, couldn’t have come at more opportune time
• The company’s new chief financial officer brings invaluable expertise and insight in manufacturing, production and delivery

As the electric boat sector is projected to double in value in the next few years, companies operating in the industry are positioning themselves to meet — and even exceed — the expectations this growth could create. For example, Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator in the performance electric recreational boating market, has made two key announcements recently: the company unveiled its Phantom vessel, a new rotomolded, recyclable, and hard-to-damage boat (https://ibn.fm/n0Ytr), and it named an industry veteran as it transitions to the manufacturing and delivery phase (https://ibn.fm/O8OPk).

The global electric boats market is on the cusp of significant growth, with the market forecast to more than double in size, increasing from $3.3 billion in 2023 to $7.7 billion by 2030, reported ResearchandMarket.com (https://ibn.fm/0dMHk). “This remarkable expansion is set to soar at a compound annual growth rate (“CAGR”) of 13.0% from 2023 to 2030,” the report stated. “The driving force behind this surge is the escalating demand for advanced electrical systems in electric boats.

“The electric boats market is poised for transformation, driven by the increasing demand for sustainable transportation solutions, mounting environmental concerns and the evolution of electric propulsion technologies,” the report continued. “Electric boats, also referred to as e-boats or electrically powered vessels, replace traditional internal combustion engines with electric motors and batteries, delivering advantages in terms of efficiency, emissions reduction and operational cost savings.”

With that forecast in mind, Vision Marine’s unveiling of its newest e-boat offering, the Phantom, couldn’t have come at more opportune time. The company debuted the boat at the Miami International Boat Show 2024. The new vessel offers significant market advantages through its economic and environmental benefits. The company noted that the boat, which can comfortably seat up to 10 passengers, is engineered for efficiency. In addition, VMAR has the capacity to produce an estimated 300 units annually, with the potential to scale up to 1,500 units a year, at a cost that is 70% lower than that of fiberglass alternatives.

“We recognize a growing demand for rotomolded boats among our Florida clientele for several reasons,” said Roger Moore, the CEO of Nautical Ventures Marine Group, which has inked an exclusive distribution deal with VMAR. The Phantom’s affordability “enables entry-level ownership; they support both electric and gas motors, appealing to ecoconscious and traditional boaters alike; and their versatility makes the Phantom ideal for various activities, from fishing to leisure. With its 10-person capacity and maintenance-free design, the Phantom meets a wide range of needs.”

As Vision Marine gears up to meet industry demand for the new boat, the company’s new chief financial officer will bring invaluable expertise and insight. The company recently named Raffi Sossoyan as its new CFO, noting that the “strategic appointment marks a significant step as Vision Marine gears up for an ambitious phase focused on manufacturing, production, and delivery, underlining the company’s dedication to scaling its operations and enhancing its market footprint.”

Sossoyan has more than 25 years of experience in global financial and operational leadership. Most recently, he served as vice president of corporate treasury at Velan Inc., a Canadian multinational company. While there, Sossoyan managed financial operations amid global sales exceeding $370 million. Prior to that, as CFO at Valtech Fabrication Inc., he oversaw worldwide sales that totaled more than $50 million.

“Raffi’s robust experience in finance and operations within publicly listed companies, particularly his success at a TSX-listed entity, aligns perfectly with our strategic objectives as we escalate our manufacturing and delivery initiatives,” said CEO Alex Mongeon. “His leadership will be instrumental in fortifying Vision Marine’s financial strategies during this critical phase of our expansion.”

These two recent announcements underscore the Vision Marine Technologies commitment to leading the shift toward electric propulsion in the marine industry, fostering sustainability and achieving superior performance through its innovative E-Motion(TM) technology.

For more information, visit the company’s website at www.VisionMarineTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR

• Correlate Energy, a publicly traded distributed energy solutions company, has positioned itself as the go-to company given the federal government’s push for greener buildings
• The government’s proposed definition of zero operating emissions buildings, seeks consistency with a framework for long-term goal-setting
• Correlate understands these changing tides and, through its three-pronged strategy, offers building owners and management the most technologically efficient and cost-effective ways to go green

Correlate Energy (OTCQB: CIPI), a publicly traded company positioned to capitalize on America’s move toward efficient energy sourcing and use, is aware of the growing pressure for buildings to become more energy efficient. This follows the federal government’s aggressive push for greener structures and its proposed definition geared toward increasing standardization, consistency, transparency, and accountability.

According to federal definitions, a zero operating emissions building is “Highly energy efficient, free of on-site emissions from energy use, and powered solely by clean energy sources.” The objective of this definition is to achieve consistency and lay down a framework for long-term goal setting. It leverages a building’s energy use as a foundation, offering incentives for existing building owners to improve their overall energy efficiency while providing a roadmap for new buildings to achieve energy efficiency upon construction (https://ibn.fm/aZIAW).

Correlate already recognizes that the energy grid in the U.S. is insufficient for the booming clean energy trend. In addition, it acknowledges that the current infrastructure poses a limit to green energy distribution. Still, it remains committed to helping buildings achieve net zero operating emissions, mainly by constructing the needed infrastructure to address this demand imbalance, while offering four main benefits with its offering. These include real cost savings, project investment funding, consistent long-term incentives, and robust customer demand.

Through its strategy of selling, retaining, and acquiring, Correlate has managed to carve out a significant market share. It is positioning itself as the all-in-one brand for total clean energy solutions, especially as the conversation around zero emissions buildings continues to proliferate and more stringent regulations are enforced.

This market positioning has seen various companies in the U.S. procure its products and services. Recently the company commissioned one of Illinois’ latest rooftop solar facilities for Continental Envelope’s manufacturing plant. This project is set to supply approximately 20-25% of the facility’s overall energy requirements (https://ibn.fm/mUav7). It has now also completed a solar project at American Tire Distributors headquarters in Huntersville, North Carolina. This project is expected to economically reduce CO2 emissions by 5,463 tons over the next two decades, helping the company reduce its carbon footprint (https://ibn.fm/jn0hz).

As the federal government continues its push for net zero emissions buildings, Correlate anticipates a growth in the demand for its products and services. In 2023, over $1.7 trillion was estimated to be invested in technologies such as solar and wind power, electric vehicles, and batteries, making it the most ever spent on clean energy in a single year. It is projected that 2024 might surpass that figure, and Correlate is positioning itself to ride the wave. With its tried and tested solutions, the company has already asserted itself as the go-to brand for decentralized energy generation.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.Correlate.Energy/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• SenesTech, a rapidly growing company specializing in highly effective fertility control solutions for animal pests, recently announced multiple product distribution deals outside the U.S.
• In Europe, it entered into an agreement with Q-chem, a pest control product supplier in The Netherlands
• In Australia, SenesTech entered into an agreement with Evicom, an environmental management firm with distribution in the country, as well as in New Zealand and the surrounding region
• In Asia, the company partnered with Agro Technic PTE Ltd, a pest control product manufacturer and distributor headquartered in Singapore

SenesTech (NASDAQ: SNES), a rodent fertility control solutions provider, and the inventor of the only EPA-registered contraceptive for male and female rats, is pleased to announce multiple distribution deals globally in what marks a huge milestone for the company, just two months into the new year. These deals bring YTD 2024 total revenue up more than 80% compared to YTD 2023 (https://ibn.fm/D9icH).

SenesTech also announced its foray into the European market with its distribution agreement with Q-chem, a pest control product supplier in the Netherlands. The move looks to tap into the growing demand for pest control products and services since the country first implemented an Integrated Pest Control (“IPM”) program four years ago with the explicit goal of reducing the reliance on anti-coagulant rodenticides. With its Evolve product, SenesTech is confident that it will dominate this market and become a leader in controlling rats with fertility control.

“Q-chem is a perfect partner for SenesTech as we begin our expansion into Europe, and Evolve(TM) fits into their portfolio perfectly,” noted Mr. Fruendt (https://ibn.fm/6VwGH).

SenesTech is following the country’s requisite regulatory procedure with Q-chem’s help. The process is expected to progress quickly, after which the product will be introduced in Europe.

New Zealand and Australia have also been prime potential markets for SenesTech. Its distribution agreement with Evicom, an environmental management firm based in Australia with distribution throughout Australia, New Zealand, and the surrounding region, opens the company to these two lucrative markets.

“Evicom is thrilled to be appointed exclusive distributors of Evolve for Australia and New Zealand,” noted Simon de Bono, Evicom’s Managing Director.

“Knowing SenesTech really cares about humanely managing animal populations through innovative fertility control aligns with our business strategy,” he added (https://ibn.fm/0nLNe).

SenesTech also announced a distribution agreement with Agro Technic PTE Ltd, a Singapore pest control product manufacturer and distributor. This agreement will cover both a substantial initial stocking order and annual minimums. It will open SenesTech up to Singapore and surrounding regions, expanding its market reach and the potential number of customers it could acquire.

“Agro Technic has been at the forefront of bringing in innovative solutions for the public health sector since the 1970s. We continue to do so year on year, bringing to market solutions that are not only environmentally friendly but, most importantly, effective!” noted Heng Yiwei, Agro Technic’s Managing Director.

“The product range that SenesTech offers, is a perfect fit to our business model, long-term strategy, and market positioning and runs in tandem with the requirements of our garden city,” he added (https://ibn.fm/l2puL).

SenesTech’s management is optimistic that these distribution agreements, coupled with its superior, tried and tested Evolve product, will set the company up for even more success this year, even as it continues to explore new growth opportunities.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

Directors, managers, VPs, regulatory affairs personnel, and service providers of the logistics and operations verticals for the biopharma supply chain across Europe and North America are invited to attend the 3rd BioPharma Supply Chain & Logistics Nexus Conference being held April 25-26, 2024, at the Basel Mariott Hotel, Switzerland. The event aims to address critical issues and challenges in the supply chain and logistics within the biopharmaceutical industry.

The event is hosted by BioPharma Nexus, a premier company organizing prestigious conferences aiming to foster networking and business ties between pharmaceutical and biotech companies and their service providers. The focus lies in building robust relations such that the best healthcare services are available to patients worldwide. Service providers, managers, and company heads can identify and connect with partners to foster important scientific and healthcare collaborations.

Benefits of attending the conference:

• Establishing networking and business relations among powerful industry leaders.
• Gain insightful knowledge and learn about the latest trends in the biopharma spectrum.
• Connect with the industry leaders to stay updated with the latest technological advancements as well as the target audience.
• Learn the latest offerings and get innovative ideas and solutions for business operations.
• Showcase your product and business solutions on a unified conference platform.

The 3rd BioPharma Nexus Conference brings together global leaders and experts on the biopharma supply chain to provide invaluable insights. They will explore topics ranging from improving the supply chain transparency and sustainability in temperature-controlled logistics to novel technologies and trends in the pharmaceutical supply chain. Special attention will be given to the issues and opportunities faced by Contract Manufacturing Organizations (CMOs/CDMOs). New entities can leverage the nexus forum to gain visibility and network with key industry stalwarts.

To know more, please visit https://ibn.fm/nPR98